Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
NEWARK, Calif., Feb. 17, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2016 financial results after the close of market, Tuesday, February 21, 2017. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
Participants can access the call by dialing (866) 643-3010 (United States) or (857) 270-6032 (International) referencing Conference ID 71033060. The conference call will also be available via a live webcast on the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
